Dr. Thomas A. Hope, MD
Claim this profileUniversity of California, San Francisco
Studies Prostate Cancer
Studies Cancer
10 reported clinical trials
15 drugs studied
Affiliated Hospitals
Clinical Trials Thomas A. Hope, MD is currently running
18F-Fluorocholine PET
for Parathyroid Adenomas
This is a prospective single arm single center Phase III study evaluating the ability of 18F-fluorocholine to detect the location of parathyroid adenomas.
Recruiting2 awards Phase 33 criteria
Ra-223
for Prostate Cancer
This phase II trial studies how well prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans (in combination with bone scans) work in selecting patients for Ra-223 radiation therapy that have castration-resistant prostate cancer that has spread from where it first started (primary site) to the bones (bone metastasis). Ra-223 is a type of therapy that emits radiation. Radiation gives off energy which can kill tumor cells and other cells that may support the tumor cells. Ra-223 is given by infusion into the veins, where it is absorbed by the bones. PSMA PET is a type of scan used to detect prostate cancer tumors. PSMA is a radioactive tracer that binds to a specific protein that is found on prostate tumor cells. The PSMA tracer shows the areas on the PET scan where tumor cells are active. A PET scan uses a special camera to detect the energy given off from radioactive tracers (such as PSMA) to make detailed pictures of areas where the tracer accumulates in the body. The PET scan is often combined with a magnetic resonance imaging (MRI) or computed tomography (CT) scan, which helps to map the locations where PSMA has accumulated. PSMA PET scans may be able to select patients that will benefit the most from Ra-223 treatment.
Recruiting1 award Phase 2
More about Thomas A. Hope, MD
Clinical Trial Related3 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Thomas A. Hope, MD has experience with
- Positron Emission Tomography Combined With Magnetic Resonance Imaging (PET/MRI)
- Whole Body Magnetic Resonance Imaging With Diffusion-Weighted Imaging (WB-MRI-DWI)
- FAP-2286
- 18F-Fluorocholine
- PSMA Positron Emission Tomography (PET) Scan
- Radium-223
Breakdown of trials Thomas A. Hope, MD has run
Prostate Cancer
Cancer
Uterine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Thomas A. Hope, MD specialize in?
Thomas A. Hope, MD focuses on Prostate Cancer and Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Thomas A. Hope, MD currently recruiting for clinical trials?
Yes, Thomas A. Hope, MD is currently recruiting for 4 clinical trials in San Francisco California. If you're interested in participating, you should apply.
Are there any treatments that Thomas A. Hope, MD has studied deeply?
Yes, Thomas A. Hope, MD has studied treatments such as Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI), Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI), FAP-2286.
What is the best way to schedule an appointment with Thomas A. Hope, MD?
Apply for one of the trials that Thomas A. Hope, MD is conducting.
What is the office address of Thomas A. Hope, MD?
The office of Thomas A. Hope, MD is located at: University of California, San Francisco, San Francisco, California 94115 United States. This is the address for their practice at the University of California, San Francisco.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.